SKU: F055  / 
    CAS Number: 99665-00-6

    Flomoxef Free Acid

    $120.00

    Flomoxef Free Acid (syn: Flomoxef) is a β-lactam antibiotic, an oxa-1 cephamycin belonging to the oxacephem group. It has broad-spectrum activity against Gram-negative and Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA). It was synthesized in 1982 by Shionogi & Co, Osaka, Japan.

    Unlike Latamoxef, it has [1-(2-hydroxethyl)-1H-tetrazol-5'yl] thiomethyl (HTT) as a side chain at the 3'-position of the cephem group instead of NMTT, and it also has a modification of 7 beta-amino side chain. 

    Flomoxef Free Acid is soluble in DMSO.  It has comparable biological activity to Flomoxef Sodium.

    We also offer:

    • Flomoxef Sodium (F041)
    Mechanism of Action Flomoxef is a β-lactam inhibitor that acts by inhibiting cell-wall synthesis. This is performed by binding to penicillin-binding protein via competitive inhibition. This prevents the formation of an antibiotic-inhibitor complex thus preventing the transpeptidation step of peptidoglycan synthesis in bacterial cell walls, leading to the inhibition of cell-wall biosynthesis.
    Spectrum Flomoxef has broad-spectrum activity against Gram-negative and Gram-positive bacteria including methicillin-resistant Staphylocccus aureus (MRSA). It is also active against Nocardia.
    Microbiology Applications Flomoxef is commonly used in clinical in vitro microbiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against Gram-positive and Gram-negative microbial isolates. Medical microbiologists use AST results to recommend antibiotic treatment options.  Representative MIC values include:
      • B. fragilis  0.5 µg/mL – ≥ 128 µg/mL
      • MRSA  4 µg/mL - ≥ 16 µg/mL

    For a representative list of Flomoxef MIC values, click here.

    Molecular Formula C15H18F2N6O7S2
    References

    Cazzola M et al (1993) Flomoxef, a new oxacephem antibiotic, does not cause hemostatic defects. Int. J. Clin. Pharmacol. Ther. Toxicol. 31(3):148-152 PMID 8468113

    Gilman AG, Rall TW, and Nies AS (eds) (1990)  Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed. Macmillan Publishing Co, New York, NY

    Ito M and Ishigami T (1991)  The meaning of the development of Flomoxef and clinical experience in Japan.  Infection 19 (suppl 5):S253-S257  PMID 1783441

    Kitahara T et al (2004)  Antimicrobial activity of saturated fatty acids and fatty amines against Methicillin-resistant Staphylococcus aureus. Biol. Pharm. Bull. 27(9):1321-1326  PMID 15340213

    Ruckdeschel G and Eder W (1988)  Comparative in vitro activity of the new oxacephem antibiotic, Flomoxef. Eur. J. Clin. Microbiol. Infect. Dis. 7:687-691  PMID 3143586

    Simon C, Simon M and Plieth C et al (1988) In vitro activity of Flomoxef in comparison to other cephalosporins. Infection 16(2):131-4 PMID 3372024

    Tsuji T, Satoh H, Narisada M, Hamashima Y and Yoshida T (1985)  Synthesis and antibacterial activity of 6315-S, a new member of the oxacephem antibiotic. J. Antibiotics 38 (4):466-476 PMID 4008339

    Yazawa K, Mikami Y, Uno J, Otozai K, Arai T (1989)  In-vitro activity of Flomoxef, a new oxacephem group antibiotic, against Nocardia in comparison with other cephalosporins. J. Antimicrob. Chemother. 24(6):921-925  PMID 2621177